Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05586971 · ClinicalTrials.gov registry record · Phase 3
Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients
A Phase 3 study, sponsored by LG Chem.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,202
- Enrollment target
NCT05586971: Completed Phase 3 study, sponsored by LG Chem.
NCT05586971 is a Phase 3 study that has completed, run by LG Chem. The registered enrollment target is 2,202 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (185% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05586971, a Phase 3 study, has completed, sponsored by LG Chem.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,202 participants
- Enrollment target
Study Summary
The aim of this 12-month randomized multi-regional double-blind parallel group allopurinol and placebo-controlled phase 3 study is to assess the efficacy and safety of three different doses of Tigulixostat in gout patients with hyperuricemia.
Primary Outcome
Serum uric acid (sUA) level will be measured at Month 4,5, and 6
Interventions
- DRUG Placebo
- DRUG Allopurinol
- DRUG Tigulixostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,202 participants |
| Start Date | 2023-03-30 |
| Est. Completion | 2025-05-06 |
| Phase | Phase 3 |
What the finished NCT05586971 record still lists
NCT05586971 is an interventional study that assigns participants to a tested intervention. Its 2,202 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (185% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05586971 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05586971 about?
NCT05586971 is a clinical study titled "Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients". The aim of this 12-month randomized multi-regional double-blind parallel group allopurinol and placebo-controlled phase 3 study is to assess the efficacy and safety of three different doses of Tigulixostat in gout patients with hyperuricemia.
What is the current status of trial NCT05586971?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,202 participants. The study started on 2023-03-30. Estimated completion is 2025-05-06.
What interventions are being tested in trial NCT05586971?
The interventions under investigation include: Placebo (DRUG), Allopurinol (DRUG), Tigulixostat (DRUG).
Who is sponsoring clinical trial NCT05586971?
This trial is sponsored by LG Chem, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05586971's enrollment target sits among peer trials
2,202 95th of 2000 higher than 1,906 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05654207 · 2,200 participants · NA
WeCare: A System of Care for Black Youth
- NCT06144554 · 2,200 participants
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
- NCT06526988 · 2,200 participants · NA
Implementation and Interaction of Clinician And Patient-facing Tools Aiming to Intensify Neurohormonal Medicines for Heart Failure
- NCT06682650 · 2,200 participants · NA
Implementation of a ColoRectal Cancer Screening Tool in US Primary Care Practices - Usual Quality Improvement (10 Clinics) vs Normalization Process Theory-Participatory Learning in Action (10 Clinics)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI